XML 19 R15.htm IDEA: XBRL DOCUMENT v3.19.3
Note 9 - Intangible Assets
 9 Months Ended
Sep. 30, 2019
Notes to Financial Statements  
Goodwill and Intangible Assets Disclosure [Text Block]
9.
  
Intangible Assets
 
Intangible assets as of
September 30, 2019
and
December 31, 2018
consisted of the following:
 
        September 30, 2019   December 31, 2018    
    Gross
Value		   Accumulated
Currency
Translation
Adjustment		   Impairment   Accumulated
Amortization		   Net Book
Value		   Accumulated
Currency
Translation
Adjustment		   Accumulated
Amortization		   Net Book
Value		   Useful
Life
Developed technology   $
17,100
     $
(3,056
 )   $
(303
 )   $
(9,448
 )   $
4,293
     $
(2,824
 )   $
(8,672
 )   $
5,604
      
15
  
In-process research & development    
4,406
      
(1,316
 )    
-
      
-
      
3,090
      
(1,168
 )    
-
      
3,238
      
Indefinite
  
Distributor relationships    
4,700
      
(415
 )    
-
      
(4,285
 )    
-
      
(415
 )    
(4,285
 )    
-
      
5
  
Patents    
1,000
      
(184
 )    
-
      
(519
 )    
297
      
(169
 )    
(482
 )    
349
      
16
  
Elevess trade name    
1,000
      
-
      
-
      
(1,000
 )    
-
      
-
      
(1,000
 )    
-
      
9
  
Total   $
28,206
     $
(4,971
 )   $
(303
 )   $
(15,252
 )   $
7,680
     $
(4,576
 )   $
(14,439
 )   $
9,191
      
 
  
 
The aggregate amortization expense related to intangible assets was
$0.3
million and
0.2
million for the
three
-month periods ended
September 30, 2019
and
2018,
respectively. The aggregate amortization expense related to intangible assets was
$0.8
million for each of the
nine
-month periods ended
September 30, 2019
and
2018.
 
The Company recorded a
$0.3
million impairment charge for the HYALOSPINE developed technology asset in the
three
-month period ended
March 31, 2019.
HYALOSPINE was an adhesion prevention gel for use after spinal surgery and received initial CE Mark approval in
January 2015.
In
March 2019,
the Company made the decision
not
to renew the CE Mark as the product was
not
aligned with the Company’s core strategic focus. As a result, an impairment charge was recorded. This amount is included in selling, general & administrative expenses on the Company’s condensed consolidated statements of operations. 
 
Through
September 30, 2019,
except as set forth in this paragraph, there have
not
been any other events or changes in circumstances that indicate that the carrying value of the other acquired intangible assets
may
not
be recoverable. The Company was notified by the distributor of MEROGEL INJECTIBLE that it would
not
continue to order the product from the Company or market the product. As a result, the depreciation schedule of the remaining
$0.1
million of net book value was accelerated. The Company continues to monitor and evaluate the financial performance of its business including the impact of general economic conditions, to assess the potential for the fair value of the reporting unit to decline below its recorded amount.